the way I see it other companies will have to do biosimilars (run trials to get their products approved) whereas they can probably get away with biogeneric because they may not need trials.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.